🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Pfizer Inc. PFE SPX

Healthcare · Drug Manufacturers - General · United States
https://www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

READ MORE ›
$26.18
+19.24% 1Y

Market & Price

Market Cap
$149.21B
Current Price
$26.18
High / Low (52W)
$28.09 / $21.61
Beta
0.30

Valuation

Stock P/E
19.98
Industry PE
23.65
Forward P/E
9.23
PEG Ratio
13.77
Book Value
$15.81
Price to Book
1.66
P/S
2.36
EV/EBITDA
7.90
Dividend Yield
6.57%

Profitability & Returns

ROCE
5.95%
ROE
8.31%
ROA
5.69%
Profit Margin
11.83%
Op Margin
31.62%
EPS (Latest Qtr)
$0.47
EPS (TTM)
$1.31

Balance Sheet & Liquidity

Debt/Equity
0.72
Quick Ratio
0.85
Current Ratio
1.25
Debt
$64.73B
Total Assets
$208.16B
Current Assets
$42.90B
Working Capital
$5.91B

Ownership

Promoter Holding
0.10%
Chg in Prom Hold
-
FII / Inst Holding
69.39%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
$201.16B
Total Revenue (TTM)
$63.32B
EBITDA
$25.46B
Free Cash Flow
$12.38B
Operating Cash Flow
$11.98B
Shares Outstanding
5.70B
Gross Margin
74.80%
Payout Ratio
131.30%

Growth (CAGR)

Revenue 5Y
-14.80%
Profit 5Y
-37.20%
Revenue (YoY)
5.40%
Earnings (YoY)
-10.10%

PROS

  • Attractive dividend yield of 6.57%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -14.8% CAGR over 5 years.
  • Earnings shrank at -37.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PFE Pfizer Inc. SPX 26.18 19.98 $149.21B 6.57% 5.95% 8.31% -14.80% -37.20%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Apr 2016Jul 2016Oct 2016Apr 2017Jul 2017Oct 2017Apr 2018Jul 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Apr 2021Jul 2021Oct 2021Apr 2022Jul 2022Oct 2022Apr 2023Jul 2023Oct 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------12.90B13.17B12.91B13.47B13.30B13.12B13.26B12.68B10.08B9.86B10.28B14.52B18.90B24.04B25.66B27.74B22.64B-------13.71B14.65B16.65B17.56B14.45B
Cost of Revenue -----------------------------------2.85B3.78B4.17B5.27B3.55B
Gross Profit -----------------------------------10.87B10.88B12.48B12.29B10.90B
Operating Expenses -----------------------------------6.45B7.11B8.35B8.81B6.77B
Operating Income -----------------------------------4.42B3.77B4.14B3.48B4.13B
EBITDA -----------------------------------5.06B5.32B5.65B756.00M5.45B
Interest Expense -----------------------------------654.00M654.00M652.00M711.00M668.00M
Pretax Income -----------------------------------2.79B3.04B3.33B-1.64B3.17B
Tax Provision ------------------------------------189.00M141.00M-216.00M-2.00M461.00M
Net Income 2.59B2.33B2.91B2.67B2.38B2.63B2.13B3.04B2.05B1.35B3.12B3.07B2.84B3.56B3.87B4.11B3.88B5.05B7.68B3.35B3.49B1.47B4.88B5.56B8.15B7.86B9.91B8.61B5.54B2.33B-2.38B3.12B41.00M--2.97B2.91B3.54B-1.65B2.69B
Diluted EPS 0.390.360.450.420.380.420.340.490.330.220.510.510.470.590.650.690.680.891.360.600.620.260.860.981.421.371.731.510.970.41-0.420.550.01--0.520.510.62-0.290.47

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------52.82B52.55B40.83B40.91B41.65B-101.17B59.55B63.63B62.58B
Cost of Revenue ---------------34.34B24.95B17.85B16.07B
Gross Profit ---------------66.83B34.60B45.78B46.51B
Operating Expenses ---------------29.67B30.38B30.95B30.72B
Operating Income ---------------37.16B4.22B14.83B15.79B
EBITDA ---------------41.03B9.56B18.13B16.78B
Interest Expense ---------------1.24B2.21B3.09B2.67B
Pretax Income ---------------34.73B1.06B8.02B7.52B
Tax Provision ---------------3.33B-1.11B-28.00M-266.00M
Net Income 8.14B8.10B8.63B8.26B10.01B14.57B22.00B9.13B6.96B7.21B21.31B11.15B16.03B9.16B-31.37B2.12B8.03B7.77B
Diluted EPS 1.171.201.231.021.271.943.191.421.111.173.521.872.821.63-5.470.371.411.36

Compounded Sales Growth

5 Years:-14.80%
1 Year:5.40%

Compounded Profit Growth

5 Years:-37.20%
1 Year:-10.10%

Stock Price Performance

1 Year:+19.24%
6 Months:+5.20%
3 Months:-3.75%
1 Month:+1.34%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Sep 2009Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --111.15B-212.95B195.01B188.00B185.80B172.10B167.57B167.38B171.62B171.80B159.42B167.59B154.23B-197.21B226.50B213.40B208.16B
Current Assets -----------------51.26B43.33B50.36B42.90B
Cash & Equivalents 1.83B3.41B2.12B4.23B1.98B1.74B3.18B10.08B2.18B3.34B3.64B2.60B1.34B1.14B1.12B1.79B-416.00M2.85B1.04B1.14B
Inventory -----------------8.98B10.19B10.85B10.65B
Receivables -----------------10.95B11.57B11.46B11.87B
Total Liabilities --53.41B-122.50B106.75B105.38B104.12B95.48B95.94B102.38B111.78B100.14B95.66B104.15B90.76B-101.29B137.21B124.90B121.39B
Current Liabilities --27.01B-37.23B28.64B28.91B29.19B23.37B21.59B29.40B31.11B30.43B31.86B37.30B25.92B-42.14B47.79B42.99B36.98B
Long Term Debt --7.96B-43.19B38.41B34.93B31.04B30.46B31.54B28.74B31.40B33.54B32.91B35.95B37.13B-31.93B60.50B56.70B60.81B
Total Debt -----------------34.86B70.84B63.65B63.96B
Total Equity --57.56B-90.01B87.81B82.19B81.26B76.31B71.30B64.72B59.54B71.31B63.41B63.14B63.24B-95.66B89.01B88.20B86.48B
Shares Outstanding -----------------9.52B9.56B9.59B9.62B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 13.35B18.24B16.59B11.45B20.24B16.75B17.68B17.08B14.69B16.19B16.80B15.83B12.59B14.40B-29.27B8.70B12.74B11.70B
Investing Cash Flow 795.00M-12.84B-31.27B-492.00M1.84B6.15B-10.54B-5.65B-2.98B-7.79B-4.74B4.53B-3.94B-4.27B--15.78B-32.28B2.65B-1.35B
Financing Cash Flow -12.61B-6.56B14.48B-11.17B-20.61B-16.00B-14.97B-10.19B-10.41B-9.23B-13.35B-20.44B-8.48B-9.65B--14.83B26.07B-17.14B-10.30B
Capital Expenditure -1.88B-1.70B-1.21B-1.51B-1.66B-1.33B-1.21B-1.20B-1.40B-1.82B-1.96B-1.98B-2.05B-2.23B--3.24B-3.91B-2.91B-2.63B
Free Cash Flow 11.47B16.54B15.38B9.94B18.58B15.42B16.48B15.88B13.29B14.37B14.85B13.84B10.54B12.18B-26.03B4.79B9.84B9.07B
Net Change in Cash ----------------1.35B2.49B-1.74B49.00M
Share Buybacks 9.99B500.00M01.00B9.00B8.23B16.29B5.00B6.16B5.00B5.00B12.20B8.87B002.00B00-

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------------66.1%58.1%71.9%74.3%
Operating Margin % ---------------36.7%7.1%23.3%25.2%
Net Margin % ---------13.7%40.6%27.3%39.2%22.0%-31.0%3.6%12.6%12.4%
ROE % -14.1%9.6%9.4%12.2%17.9%28.8%12.8%10.8%12.1%29.9%17.6%25.4%14.5%-32.8%2.4%9.1%9.0%
ROCE % ---------------24.0%2.4%8.7%9.2%

Shareholding Pattern

Insiders
0.10%
Institutions
69.39%
Public Float
69.45%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.74% 498.26M $13.04B
2 Vanguard Capital Management LLC 6.48% 369.43M $9.67B
3 State Street Corporation 5.29% 301.59M $7.90B
4 Geode Capital Management, LLC 2.34% 133.56M $3.50B
5 Vanguard Portfolio Management LLC 2.05% 116.73M $3.06B
6 Fisher Asset Management, LLC 1.84% 104.96M $2.75B
7 Morgan Stanley 1.63% 92.69M $2.43B
8 Northern Trust Corporation 1.09% 62.03M $1.62B
9 Massachusetts Financial Services Co. 1.00% 56.91M $1.49B
10 State Farm Mutual Automobile Insurance Co 0.96% 54.51M $1.43B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PFE

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks